About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 703 record(s)
Req # A-2022-000348
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-120713-906.Organization: Health Canada
March 2023
Req # A-2022-000576
Adverse Drug Reactions (ADRs). Report numbers: E2B_02895902, E2B_05128231, E2B_05053764, E2B_04987109, E2B_04966727, E2B_05015795, E2B_04821910, E2B_03587846, E2B_04914551, E2B_04342934.Organization: Health Canada
March 2023
Req # A-2022-000626
Adverse Drug Reaction (ADR) for Hydrocortisone acetate/Pramoxine hydrochloride. Report number: 000996794.Organization: Health Canada
March 2023
Req # A-2022-000902
Adverse Drug Reactions (ADRs) for Pantoprazole sodium. Report numbers: E2B_05566840, E2B_05589438, E2B_05575121, E2B_05591402, E2B_05552008. ADRs for Mesalazine. Report numbers: E2B_05530426, E2B_05557453, E2B_05596202, E2B_05554526. ADR for…Organization: Health Canada
March 2023
Req # A-2022-000959
Adverse Drug Reaction (ADR) for FLUDROCORTISONE ACETATE. Report number: E2B_05047013.Organization: Health Canada
March 2023
Req # A-2022-001103
Adverse Drug Reactions (ADRs). Report numbers: E2B_05695465, E2B_05616978, E2B_05611951, E2B_05627811, E2B_05627858, E2B_05674706, E2B_05652133, 001004932, E2B_05641696, E2B_05635869.Organization: Health Canada
March 2023
Req # A-2022-001114
Adverse Drug Reactions (ADRs) for ALENDRONIC ACID. Report numbers: 000721558, 000721558, E2B_02036075, E2B_02036047, E2B_02036081, 000714891, 000720913, 000715963, 000721496, E2B_01688718.Organization: Health Canada
March 2023
Req # A-2022-001135
Adverse Drug Reaction (ADR) for DEXILANT. Report number: 001009537. ADRs for ENTYVIO. Report numbers: 001009153, 001010630, E2B_05776851, E2B_05747661, E2B_05725356, E2B_05766145. ADR for VEDOLIZUMAB. Report number: 001011002.Organization: Health Canada
March 2023
Req # A-2022-001137
Adverse Drug Reaction (ADR) for NINLARO. Report number: E2B_05754329. ADRs for IXAZOMIB. Report numbers: E2B_05765887, E2B_05775462, E2B_05769970, E2B_05769961, E2B_05769964. ADRs for ONDANSETRON. Report numbers: 001014425, 001010744, E2B_05712287,…Organization: Health Canada
March 2023
Req # A-2022-001142
Adverse Drug Reaction (ADR) for VYVANSE. Report number: E2B_05734113. ADRs for C1 ESTERASE INHIBITOR (HUMAN). Report numbers: E2B_05727141, E2B_05795178, E2B_05743860, E2B_05760238. ADR for GAMMAGARD LIQUID. Report number: 001011695. ADRs for…Organization: Health Canada
March 2023